Synchronous Elevation of Soluble Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) Correlates with Gastric Cancer Progression

Nae Choon Yoo, Hyun Cheol Chung, Hei Cheol Chung, Joon Oh Park, Sun Young Rha, Joo Hang Kim, Jae Kyung Roh, Jin Sik Min, Byung Soo Kim, Sung Hoon Noh

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Soluble forms of ICAM-1 (sICAM-1) and VCAM-1 (sVCAM-1) have been reported from the supernatant of cytokine-activated endothelial cells, cancer cells and from sera of cancer patients. We measured sICAM-1 and sVCAM-1 from the serum of 20 healthy volunteers and 142 gastric cancer patients by ELISA assay. Ninety-five patients were operable and 47 patients were inoperable at the time of this study. Particularly in the 28 operable patients, we sampled both portal and peripheral blood simultaneously and measured the levels of the soluble forms of cell adhesion molecules (sCAMs). The sCAMs level and sero-positivity rate increased with cancer progression in order of the healthy controls, operable patients, and inoperable patients. In inoperable cancer, the sICAM-1 level increased more with liver metastasis. sICAM-1 and sVCAM-1 did not correlate with each other in either portal or peripheral blood. A total of 58.3% of patients with liver metastasis and 22.9% of patients without liver metastasis showed synchronous expression of both sCAMs (p=0.03). Synchronous sero-positivity of sCAMs and αFP was higher with liver metastasis (p=0.01). The median overall survival duration which co-expressed both sCAMs was 9 months. This showed a significant difference compared with the sICAMs non-expressing group, where the median survival was not reached until 24 months follow-up (p=0.002). The synchronous expression of sCAMs was an independent risk factor in gastric cancer patients. We raise the possibility that synchronous sICAM-1 and sVCAM-1 elevation may be a useful monitor to determine tumor burden in gastric cancer.

Original languageEnglish
Pages (from-to)27-36
Number of pages10
JournalYonsei medical journal
Volume39
Issue number1
DOIs
Publication statusPublished - 1998 Jan 1

Fingerprint

Vascular Cell Adhesion Molecule-1
Intercellular Adhesion Molecule-1
Stomach Neoplasms
Cell Adhesion Molecules
Neoplasm Metastasis
Liver
Neoplasms
Time and Motion Studies
Survival
Tumor Burden
Serum
Healthy Volunteers
Endothelial Cells
Enzyme-Linked Immunosorbent Assay
Cytokines

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Yoo, Nae Choon ; Chung, Hyun Cheol ; Chung, Hei Cheol ; Park, Joon Oh ; Rha, Sun Young ; Kim, Joo Hang ; Roh, Jae Kyung ; Min, Jin Sik ; Kim, Byung Soo ; Noh, Sung Hoon. / Synchronous Elevation of Soluble Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) Correlates with Gastric Cancer Progression. In: Yonsei medical journal. 1998 ; Vol. 39, No. 1. pp. 27-36.
@article{394582384a2346508358d6cb6354125b,
title = "Synchronous Elevation of Soluble Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) Correlates with Gastric Cancer Progression",
abstract = "Soluble forms of ICAM-1 (sICAM-1) and VCAM-1 (sVCAM-1) have been reported from the supernatant of cytokine-activated endothelial cells, cancer cells and from sera of cancer patients. We measured sICAM-1 and sVCAM-1 from the serum of 20 healthy volunteers and 142 gastric cancer patients by ELISA assay. Ninety-five patients were operable and 47 patients were inoperable at the time of this study. Particularly in the 28 operable patients, we sampled both portal and peripheral blood simultaneously and measured the levels of the soluble forms of cell adhesion molecules (sCAMs). The sCAMs level and sero-positivity rate increased with cancer progression in order of the healthy controls, operable patients, and inoperable patients. In inoperable cancer, the sICAM-1 level increased more with liver metastasis. sICAM-1 and sVCAM-1 did not correlate with each other in either portal or peripheral blood. A total of 58.3{\%} of patients with liver metastasis and 22.9{\%} of patients without liver metastasis showed synchronous expression of both sCAMs (p=0.03). Synchronous sero-positivity of sCAMs and αFP was higher with liver metastasis (p=0.01). The median overall survival duration which co-expressed both sCAMs was 9 months. This showed a significant difference compared with the sICAMs non-expressing group, where the median survival was not reached until 24 months follow-up (p=0.002). The synchronous expression of sCAMs was an independent risk factor in gastric cancer patients. We raise the possibility that synchronous sICAM-1 and sVCAM-1 elevation may be a useful monitor to determine tumor burden in gastric cancer.",
author = "Yoo, {Nae Choon} and Chung, {Hyun Cheol} and Chung, {Hei Cheol} and Park, {Joon Oh} and Rha, {Sun Young} and Kim, {Joo Hang} and Roh, {Jae Kyung} and Min, {Jin Sik} and Kim, {Byung Soo} and Noh, {Sung Hoon}",
year = "1998",
month = "1",
day = "1",
doi = "10.3349/ymj.1998.39.1.27",
language = "English",
volume = "39",
pages = "27--36",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "1",

}

Synchronous Elevation of Soluble Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) Correlates with Gastric Cancer Progression. / Yoo, Nae Choon; Chung, Hyun Cheol; Chung, Hei Cheol; Park, Joon Oh; Rha, Sun Young; Kim, Joo Hang; Roh, Jae Kyung; Min, Jin Sik; Kim, Byung Soo; Noh, Sung Hoon.

In: Yonsei medical journal, Vol. 39, No. 1, 01.01.1998, p. 27-36.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Synchronous Elevation of Soluble Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) Correlates with Gastric Cancer Progression

AU - Yoo, Nae Choon

AU - Chung, Hyun Cheol

AU - Chung, Hei Cheol

AU - Park, Joon Oh

AU - Rha, Sun Young

AU - Kim, Joo Hang

AU - Roh, Jae Kyung

AU - Min, Jin Sik

AU - Kim, Byung Soo

AU - Noh, Sung Hoon

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Soluble forms of ICAM-1 (sICAM-1) and VCAM-1 (sVCAM-1) have been reported from the supernatant of cytokine-activated endothelial cells, cancer cells and from sera of cancer patients. We measured sICAM-1 and sVCAM-1 from the serum of 20 healthy volunteers and 142 gastric cancer patients by ELISA assay. Ninety-five patients were operable and 47 patients were inoperable at the time of this study. Particularly in the 28 operable patients, we sampled both portal and peripheral blood simultaneously and measured the levels of the soluble forms of cell adhesion molecules (sCAMs). The sCAMs level and sero-positivity rate increased with cancer progression in order of the healthy controls, operable patients, and inoperable patients. In inoperable cancer, the sICAM-1 level increased more with liver metastasis. sICAM-1 and sVCAM-1 did not correlate with each other in either portal or peripheral blood. A total of 58.3% of patients with liver metastasis and 22.9% of patients without liver metastasis showed synchronous expression of both sCAMs (p=0.03). Synchronous sero-positivity of sCAMs and αFP was higher with liver metastasis (p=0.01). The median overall survival duration which co-expressed both sCAMs was 9 months. This showed a significant difference compared with the sICAMs non-expressing group, where the median survival was not reached until 24 months follow-up (p=0.002). The synchronous expression of sCAMs was an independent risk factor in gastric cancer patients. We raise the possibility that synchronous sICAM-1 and sVCAM-1 elevation may be a useful monitor to determine tumor burden in gastric cancer.

AB - Soluble forms of ICAM-1 (sICAM-1) and VCAM-1 (sVCAM-1) have been reported from the supernatant of cytokine-activated endothelial cells, cancer cells and from sera of cancer patients. We measured sICAM-1 and sVCAM-1 from the serum of 20 healthy volunteers and 142 gastric cancer patients by ELISA assay. Ninety-five patients were operable and 47 patients were inoperable at the time of this study. Particularly in the 28 operable patients, we sampled both portal and peripheral blood simultaneously and measured the levels of the soluble forms of cell adhesion molecules (sCAMs). The sCAMs level and sero-positivity rate increased with cancer progression in order of the healthy controls, operable patients, and inoperable patients. In inoperable cancer, the sICAM-1 level increased more with liver metastasis. sICAM-1 and sVCAM-1 did not correlate with each other in either portal or peripheral blood. A total of 58.3% of patients with liver metastasis and 22.9% of patients without liver metastasis showed synchronous expression of both sCAMs (p=0.03). Synchronous sero-positivity of sCAMs and αFP was higher with liver metastasis (p=0.01). The median overall survival duration which co-expressed both sCAMs was 9 months. This showed a significant difference compared with the sICAMs non-expressing group, where the median survival was not reached until 24 months follow-up (p=0.002). The synchronous expression of sCAMs was an independent risk factor in gastric cancer patients. We raise the possibility that synchronous sICAM-1 and sVCAM-1 elevation may be a useful monitor to determine tumor burden in gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031992583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031992583&partnerID=8YFLogxK

U2 - 10.3349/ymj.1998.39.1.27

DO - 10.3349/ymj.1998.39.1.27

M3 - Article

C2 - 9529982

AN - SCOPUS:0031992583

VL - 39

SP - 27

EP - 36

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 1

ER -